Durvalumab [Imfinzi]

[MAF] Durvalumab (Imfinzi) Concentrate For Infusion 120 mg/2.4 mL, 500 mg/10 mL

1. Consolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy.
   Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 12 months. Durvalumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression.

2. Durvalumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer.

3. Durvalumab in combination with a single priming dose of tremelimumab for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.

4. Treatment of unresectable hepatocellular carcinoma in patients who had received a priming dose of tremelimumab and have adequate liver function as assessed by the Child-Pugh scoring system.

[MSHL] Durvalumab Concentrate For Solution For Infusion 120 mg/2.4 mL, 500 mg/10 mL

1. Consolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 12 months. Durvalumab retreatment is allowed at time of progression for up to 1 additional year if the initial treatment was stopped for reasons other than disease progression.

2. Durvalumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer.

3. Durvalumab in combination with cisplatin and gemcitabine for the treatment of patients with locally advanced or metastatic biliary tract cancer.

4. Treatment of unresectable hepatocellular carcinoma in patients who had received a priming dose of tremelimumab and have adequate liver function as assessed by the Child-Pugh scoring system.

[MSHL] Durvalumab Concentrate For Solution For Infusion 120 mg/2.4 mL, 500 mg/10 mL

1. Durvalumab in combination with a single priming dose of tremelimumab for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.

View legend

16/09/2025 Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combination with platinum-based chemotherapy, then as maintenance with or without olaparib, for inclusion on the MOH List of Subsidised Drugs for patients with untreated primary advanced or recurrent endometrial cancer. The decision was based on the uncertainties surrounding the magnitude of clinical benefit compared with chemotherapy, and unfavourable cost-effectiveness compared with chemotherapy and dostarlimab.

Clinical indication, subsidy class and MediShield Life claim limit for durvalumab and olaparib are provided in the Annex.

01/08/2025 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

The Ministry of Health’s Drug Advisory Committee has reviewed all available treatments for cancer to update the MOH List of Subsidised Drugs in line with local clinical practice and medical advancements. As part of this review, Technology Guidances have been prepared which describe the subsidy recommendations for many cancer drugs for specific clinical conditions. The remaining treatments which have been considered by the Committee are included in this document.

[R] Based on the available evidence, the Ministry of Health’s Drug Advisory Committee has recommended:

• Abemaciclib 50 mg, 100 mg and 150 mg tablets;

• Abiraterone acetate 250 mg tablets;

• Afatinib 20 mg, 30 mg and 40 mg tablets;

• Alectinib 150 mg capsule;

• Anagrelide 0.5 mg capsule;

• Atezolizumab 840 mg/14 mL and 1200 mg/20 mL concentrate for solution for infusion;

• Avelumab 200 mg/10 mL concentrate for solution for infusion;

• Axitinib 1 mg and 5 mg tablets;

• Azacitidine 100 mg injection;

• Bendamustine 25 mg and 100 mg concentrate for infusion;

• Bicalutamide 50 mg tablet;

• Bortezomib 3.5 mg injection;

• Brentuximab vedotin 50 mg powder for concentrate for solution for infusion;

• Brigatinib 30 mg, 90 mg and 180 mg tablets;

• Cabozantinib 20 mg, 40 mg and 60 mg tablets;

• Ceritinib 150 mg capsule;

• Cetuximab 100 mg/20 mL solution for infusion;

• Cisplatin 100 mg/100 mL concentrate for infusion;

• Cyproterone 50 mg tablet;

• Dabrafenib 50 mg and 75 mg capsules;

• Dasatinib 20 mg, 50 mg and 70 mg tablets;

• Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion;

• Epirubicin 50 mg/25 mL injection;

• Eribulin mesylate 1 mg/2 mL solution for injection;

• Erlotinib 100 mg and 150 mg tablets;

• Exemestane 25 mg tablet;

• Fludarabine phosphate 50 mg injection;

• Fulvestrant 250 mg/5 mL solution for injection;

• Gefitinib 250 mg tablet;

• Gilteritinib fumarate 40 mg tablet;

• Goserelin 3.6 mg and 10.8 mg depot injections;

• Imatinib 100 mg and 400 mg tablets;

• Ipilimumab 50 mg/10 mL concentrate for solution for infusion;

• Lapatinib 250 mg tablets;

• Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules;

• Leuprorelin acetate 3.75 mg and 11.25 mg depot injection;

• Lorlatinib 25 mg and 100 mg tablets;

• Megestrol 40 mg and 160 mg capsules;

• Midostaurin 25 mg capsule;

• Nilotinib 50 mg, 150 mg and 200 mg capsules;

• Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion;

• Obinutuzumab 1000 mg/40 mL concentrate for solution for infusion;

• Olaparib 100 mg and 150 mg tablets;

• Oxaliplatin 200 mg/40 mL concentrate for infusion;

• Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension;

• Palbociclib 75 mg, 100 mg and 125 mg capsules/tablets;

• Pazopanib 200 mg and 400 mg tablets;

• Pegylated liposomal doxorubicin 20 mg concentrate for infusion;

• Pembrolizumab 100 mg/4 mL solution for infusion;

• Pemetrexed 100 mg and 500 mg injections;

• Ponatinib 15 mg tablet;

• Ribociclib 200 mg tablet;

• Ruxolitinib 5 mg, 15 mg and 20 mg tablets;

• Somatropin 5 mg/1.5 mL and 10 mg/1.5 mL prefilled pens and solution for injection;

• Somatropin 4 mg and 5.3 mg/mL powder and solvent for solution for injection;

• Somatropin 5.83 mg/mL and 8 mg/mL solution for injection;

• Sunitinib 12.5 mg capsules;

• Trametinib 0.5 mg and 2 mg tablets; and

• Vinorelbine 50 mg/5 mL injection

for inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness.

[NR] Drugs that have not been recommended for subsidy are listed in the Annex.

For all drugs, the clinical indications, subsidy class, subsidy implementation dates (if applicable), and MediShield Life claim limits are provided in the Annex.

04/06/2025 Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma

The Ministry of Health’s Drug Advisory Committee has recommended:

• Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, to be used according to the STRIDE regimen (single-dose tremelimumab in combination with regular-interval durvalumab) for treating unresectable hepatocellular carcinoma. Patients must not have received prior systemic therapy and must have adequate liver function as assessed by the Child-Pugh scoring system.

Funding status

[R] Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.

Clinical indication, subsidy class and MediShield Life claim limits for durvalumab and tremelimumab are provided in the Annex.

View legend

PMG 16/10/2025 IMFINZI® (durvalumab): PATIENT MEDICATION GUIDE

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration